Skip to main content
12/31/2019

Happy New Year

Happy New Year! With gratitude, we recognize your thoughtful support and contributions. Thanks to your continued generosity in 2020, we will continue to lead the fight towards treatments and a cure.

Continue Reading
12/18/2019

Latiglutenase for Celiac Disease Shows Symptom, Quality of Life Improvement

ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe and effective in reducing the symptoms of seropositive celiac disease patients on a gluten-free diet. A significant improvement in both symptom severity and quality of…

Continue Reading